2.6K(top 0.1%)
papers
125.3K(top 0.1%)
citations
148(top 0.1%)
h-index
302(top 0.1%)
g-index
2.7K
all documents
137.8K
doc citations
7.3K
citing journals

Top Articles

#TitleJournalYearCitations
1Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine20156,773
2Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet, The20165,456
3Guidelines for the use and interpretation of assays for monitoring autophagyAutophagy20123,122
4The biology and management of non-small cell lung cancerNature20182,877
5Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncology, The20152,353
6How We Design Feasibility StudiesAmerican Journal of Preventive Medicine20092,233
7MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature20142,109
8American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology20071,998
9Longitudinal analyses reveal immunological misfiring in severe COVID-19Nature20201,710
10Pembrolizumab for Early Triple-Negative Breast CancerNew England Journal of Medicine20201,542
11Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter StudyJournal of Clinical Oncology20111,501
12A History of Cancer ChemotherapyCancer Research20081,362
13Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction CancerJAMA Oncology20181,350
14Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncology, The2012995
15Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialLancet, The2018984
16Analysis of Fusobacterium persistence and antibiotic response in colorectal cancerScience2017983
17Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019943
18Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology2012931
19Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyJournal of Clinical Oncology2016868
20Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional studyLancet Haematology,the2020848
21Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2020848
22Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2017762
23Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2016760
24FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisLancet Oncology, The2016719
25Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCancer Discovery2015696
26Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung CancerNew England Journal of Medicine2018691
27Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateJournal of Clinical Oncology2020673
28Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019672
29ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate CancerJournal of Clinical Oncology2019643
30Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric CancerJAMA Oncology2020611
31Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialLancet Oncology, The2016594
32Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnnals of Oncology2013567
33Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2022562
34Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNature Communications2016550
35Prostate Cancer, Version 1.2016Journal of the National Comprehensive Cancer Network: JNCCN2016544
36Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronismNature Genetics2013519
37Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCJournal of Thoracic Oncology2018515
38Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung CancerCancer Discovery2017507
39Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialJournal of Clinical Oncology2017506
40Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2017451
41Immunotherapy in Non–Small Cell Lung Cancer: Facts and HopesClinical Cancer Research2019447
42Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology2016444
43Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung CarcinomaJAMA Oncology2018437
44Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJournal of Clinical Oncology2018431
45A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Annals of Oncology2018424
46Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology2019404
47Classification of current anticancer immunotherapiesOncotarget2014395
48Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) StudyJournal of Clinical Oncology2015394
49NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018Journal of the National Comprehensive Cancer Network: JNCCN2018394
50Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019393